Gene-Targeted cancer therapy put to the test in major trial

NCT ID NCT02152254

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether choosing cancer treatment based on the genetic makeup of a patient's tumor works better than standard therapy. Over 1,300 people with metastatic cancer are randomly assigned to receive either a targeted drug matched to their tumor's mutations or standard care. The goal is to see if personalized treatment can delay cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: targeted therapy based on molecular profiling
What this could lead to: If successful, this could show that personalizing cancer treatment based on a tumor's genetic changes helps patients live longer without their cancer growing.
What could go wrong: This is a phase 2 trial, so results are still early. It may not prove that genetic profiling improves survival, and some targeted therapies may have side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANT NEOPLASM RECURRENT MALIGNANT NEOPLASM

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.